Noble N H
Quality Assurance, Burroughs Wellcome Co., Greenville, North Carolina.
J Parenter Sci Technol. 1993 Jan-Feb;47(1):26-8.
Environmental monitoring is an essential requirement in the pharmaceutical industry. Results which the manufacturer obtains from environmental monitoring must be reproducible and assure that the aseptic environment is under control. Today, more than ever, environmental data is scrutinized during FDA CGMP and preapproval NDA inspections and this trend will likely continue. Environmental test methods which have been in existence for years are accepted throughout the industry, but the user must bear the responsibility of proving that the methods yield reproducible results. New test methodologies must be validated to be as good as or better than the methods they are replacing. Currently, environmental result alert/action levels in existing facilities should be based on industry guidelines and facility performance validation. The pharmaceutical manufacturer must demonstrate that the levels which have been established for the facility have a statistical basis related to the historical performance of the facility. As time goes on, environmental levels may be readjusted to coincide with the operational performance levels of the facility.
环境监测是制药行业的一项基本要求。制造商从环境监测中获得的结果必须具有可重复性,并确保无菌环境处于受控状态。如今,在FDA的CGMP和批准前的NDA检查中,环境数据受到了比以往任何时候都更严格的审查,而且这种趋势可能会持续下去。多年来一直存在的环境测试方法在整个行业中都被接受,但用户必须承担证明这些方法能产生可重复结果的责任。新的测试方法必须经过验证,以达到或优于它们所替代的方法。目前,现有设施中的环境结果警戒/行动水平应基于行业指南和设施性能验证。制药制造商必须证明为该设施设定的水平具有与该设施历史性能相关的统计依据。随着时间的推移,环境水平可能会进行调整,以与设施的运行性能水平相一致。